Related Experiment Video
Updated: Feb 2, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
BET Inhibition Induces HEXIM1- and RAD51-Dependent Conflicts between Transcription and Replication
Akhil Bowry1, Ann Liza Piberger1, Patricia Rojas1
1Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Abstract:
BET bromodomain proteins are required for oncogenic transcription activities, and BET inhibitors have been rapidly advanced into clinical trials. Understanding the effects of BET inhibition on processes such as DNA replication will be important for future clinical applications. Here, we show that BET inhibition, and specifically inhibition of BRD4, causes replication stress through a rapid overall increase in RNA synthesis. We provide evidence that BET inhibition acts by releasing P-TEFb from its inhibitor HEXIM1, promoting interference between transcription and replication. Unusually, these transcription-replication conflicts do not activate the ATM/ATR-dependent DNA damage response but recruit the homologous recombination factor RAD51. Both HEXIM1 and RAD51 promote BET inhibitor-induced fork slowing but also prevent a DNA damage response. Our data suggest that BET inhibitors slow replication through concerted action of transcription and recombination machineries and shed light on the importance of replication stress in the action of this class of experimental cancer drugs.
Insights
BET inhibitors, particularly BRD4 inhibitors, induce replication stress by increasing RNA synthesis. This process involves transcription-replication conflicts that recruit RAD51, influencing DNA replication fork dynamics in cancer drug development.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- BET bromodomain proteins are crucial for oncogenic transcription.
- BET inhibitors are emerging as a promising class of cancer therapeutics.
- Understanding BET inhibition's impact on DNA replication is vital for clinical use.
Purpose of the Study:
- To investigate the effects of BET inhibition on DNA replication.
- To elucidate the molecular mechanisms underlying BET inhibitor-induced replication stress.
Main Methods:
- Assessed the impact of BET inhibition, specifically BRD4 inhibition, on cellular processes.
- Investigated the role of P-TEFb, HEXIM1, and RAD51 in response to BET inhibition.
- Analyzed the activation of DNA damage response pathways (ATM/ATR) and homologous recombination.
Main Results:
- BET inhibition, particularly of BRD4, triggers replication stress via increased RNA synthesis.
- BET inhibition releases P-TEFb from HEXIM1, leading to transcription-replication conflicts.
- These conflicts recruit RAD51, slowing replication forks without activating ATM/ATR DNA damage response.
Conclusions:
- BET inhibitors induce replication fork slowing through coordinated transcription and recombination.
- HEXIM1 and RAD51 play protective roles, preventing a DNA damage response during BET inhibition.
- Replication stress is a key mechanism in the action of BET inhibitors as experimental cancer drugs.
Related Concept Videos
Restarting Stalled Replication Forks
Master Transcription Regulators
The DNA Replication Fork
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
Transcription Factors

